T1	intervention 7 18	anastrozole
T2	control 461 468	placebo
T3	eligibility 717 783	Postmenopausal women at increased risk of developing breast cancer
T4	duration 905 912	5 years
T5	outcome-Measure 1134 1151	all breast cancer
T6	No-of-participants 1153 1157	3864
T7	duration 1179 1216	between Feb 2, 2003, and Jan 31, 2012
T8	intervention-participants 1218 1222	1920
T9	control-participants 1279 1283	1944
T10	outcome 1356 1382	reduction in breast cancer
T11	intervention-value 1352 1355	49%
T12	intervention-value 1413 1415	85
T13	control-value 1419 1422	165
T14	outcome 1487 1496	reduction
T15	outcome 1515 1528	first 5 years
T16	intervention-value 1530 1532	35
T17	control-value 1536 1538	89
T18	outcome 1590 1603	after 5 years
T19	intervention-value 1605 1607	50
T20	control-value 1611 1613	76
T21	outcome 1718 1768	Invasive oestrogen receptor-positive breast cancer
T22	intervention-value 1784 1787	54%
T23	outcome 1900 1937	reduction in ductal carcinoma in situ
T24	intervention-value 1896 1899	59%
T25	outcome 2105 2111	deaths
T26	intervention-value 2134 2136	69
T27	control-value 2140 2142	70
T28	outcome 2182 2199	for breast cancer
T29	intervention-value 2201 2204	two
T30	control-value 2220 2225	three
T31	outcome 2250 2280	decrease in non-breast cancers
T32	intervention-value 2311 2314	147
T33	control-value 2318 2321	200
T34	outcome 2414 2462	No excess of fractures or cardiovascular disease
